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Pt~rified plasma membrane vesicles isolated from multidrug-resistant human KB-VI cells accumulate [~H]vinblastlne in an energy-dependent 
manner, The accumulation of [-~H]vinblastine i  the presence of ATP is a saturable process. ATP can be replaced by other purinc nucleotide 
triphosphates, of which GTP is the most efficient. 
Multidrug resistance; Uptake: Vesicle 
1. INTRODUCTION 
The multidrug resistance (MDR) phenotype, which 
is characterized by a decreased accumulation of' hydro- 
phobic chemotherapeutic drugs by cells, is due to over- 
expression of P-170 (also known as P-glycoprotein or 
the multidrug transporter), an intrinsic plasma mem- 
brane protein encoded by the MDRI gene in human 
ceils [1-5]. The plasma membrane localization of P-170, 
together with the molecular genetic evidence that trans- 
fer of the mdr gene is sufficient o confer drug resistance 
to drag sensitive cells, suggest hat P- 170 itself is respon- 
sible for active drug efflux [6]. 
The demonstration of the drug transport properties 
of P-170 has been achieved using sealed plasma mem- 
brane vesicles isolated from KB-VI multidrug-resistant 
ceils [7,9-10]. Previously reported data with this system 
showed a requirement for ATP, and osmotic sensitivity 
of the uptake process [7,8]. The population of purified 
vesicles used to demonstrate transport consists of right- 
side-out and inverted (inside.out) vesicles. Only the in- 
side-out vesicles can accumulate drugs (e.g. 
[3H]vinblastine). In these vesicles the orientation of the 
multidrug transporter is such that the nucleotide bind- 
ing sites face the incubation medium and therefore are 
accessible to ATP. This orientation allows the translo- 
cation of vinblastine into the intravesicular space. In 
sealed vesicles, ns in intact cells, ATP does not cross the 
plasma membrane barrier, and therefore cannot drive 
the pump of right-side-o ~t vesicles, which remain silent 
in the drug transport assay but may contribute to non- 
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specific uptake by binding drug. Although P-170 has 
been shown to be an ATP.dependejat plasma membrane 
transporter a possible role for other nucleotides in drug 
transport has never been examined. We show here that, 
among numerous nucleotides tested for vinblastine ac- 
cumulation, GTP was also able to support drug trans- 
port in KB-VI vesicles. 
2. EXPERIMENTAL 
2,1, Cell clt/tlere 
The original hu,nan KB carcinoma cell line was obtained from the 
American Type Tissue Culture Collection, and the drug-resistant KB- 
V1 cell line was selected from tl~e subclone. KB.3-1, as previously 
described [11]. This vinblastine-resistant cell line was maintained in a 
constant concentration of the drug (1 #g/m]) dt~ring rowth as a 
monolayer at 37°C in 5% CO,, in Dulbeeco's modified Eagle's me- 
dium supplemented with 10% fetal calf serum (Gibco), L-glutamine (2 
raM), penicillin (50 U/ml) and streptomycin (50 ~g/ml), Cells were 
grown to confluence on 150 mm dishes (Falcon, Intergrid). 
2.2. Plaso~a tnembrane v sicle isolatioJ; 
The membrane vesicles were prepared from KB.V I cells by nitrogen 
cavitation according to the method of Lever [12], and purified as 
previously described [7], Purified vesicles (yield: 10-16 trig of vesicle 
protein from 60-80 plates) were resuspended in TS buffer (10 mM 
Tris-HCI, 250 InM sucrose and 50 mM Noel, pH 7,5) at a protein 
concentration of 2-2 mg/ml, and stored at -80°C prior to use. 
2,3, [3H]Vinbktsthte uptake b), vesicles (rapid filtrtttiott echnique) 
Drug uptake was measured in the presence of 5.3 nM 
['~H]vinblastine according to the protocol described by Horio et al, [7] 
with the following modifications, All components were prepared in TS 
buffer. The Millipore filters (HAWP, 0.45/.tin size) were pre-soaked 
in 10 mM Tris.HCl. pH 7.5, containing 10% fetal calf- or calf serum 
in order to decrease non-specific adsorption of the hydrophobic drug 
to the filters. Vinblastine was prepared as follows: 50/.tCi of [G- 
~H]vinblastine sulphate (Amersham) in methanol solutio,l was dried 
under a nitrogen stream and resuspended immediately in 200 btl of 
dimethylsalfoxide, then diluted to 320 nI~4 in 10 mM Tris-HCl, pH 7.5, 
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50 mM NaCI, filtered (0,22/aM, Millipore), and stored in aliquots at 
-80°C prior to use, The final concentration f the drug in the assay 
was 5.3 aM, The DMSO concentration was about 0.025%. Non- 
Sl~'cifi¢ association of vinblastine with the vesicles ~vas determined by 
omitting the nucleotide in the incubation medium (control). All meas- 
urements were carried out in quadruplicate. Filters were dissolved in 
Aquasol (Du Pont, NEN) prior to counting [~H]vinblastine uptake by 
the vesicles. All reported 13Hlvinblastine uptake values are corrected 
b~' subtracting the corresponding 0 rain time point, Protein concentra- 
tions were determined be the method of Bradford [I 3] using the Bio- 
Rad protein kit with bovine serum albumin as standard, 
2,4, Osmosensitlvio, of the [JH]vktbla~'thte upta~'e 
For the osmosensitivity experiments freshly thawed vesicles (50-100 
pg total protein) were pre-equilibrated for I h in TS buffer of the 
appropriate osmolarlty (determii~ed by sucrose concentration) i  the 
absence of nucleotide, MgCl~ and drug [7], The equilibration time was 
chosen from the kinetic profiles which showed no leakiness of the 
vesicles, compared to the control vesicles, during tlae 90 rain incuba- 
tion. This preequilibration time was also chosen to insure homogene- 
ily in the incubation mixture by allowing equilibration of diffusible 
molecules, Indeed° during plasma membrane iscalation (at 4°C) some 
of the hydrophobic drug molecules may still be in the membrane, and 
either become ntrapped when vesicles re.seal or remain adsorbed on 
the membranes and therefore may interfere with the uptake of the 
radiolabelled vinblastine. The uptake studies were started by addin~ 
the appropriate nucleotide and the radioactive drug in solution at the 
same sucrose concentration, and radioactivit.~¢ associated with the 
vesicles was measured l0 rain thereafter. A 0 time uptake was obtained 
by stopping the reaction by a I 0-fold dilution with TS buffer and rapid 
filtration, immediately after addition of the drug, Altogether, the time 
elapsed from the thawing of the vesicles to the final measurements 
stayed in the range in v~hich KB-VI vesicles had been shown to retain 
their ability to accumulate vinblastine. 
2,5. Materials 
All nucleotides, nudoosides, ereatine phoslahokinaga t.EC 2,7.3.2, 
from rabbit muscle type 1) and creatine phosphate were from Sigma, 
All other chemicals were of the highest avaitable analytical or spectro- 
scopic grade, 
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Fig. 1, Time.course of ATP-dependent vinblastine uptake in vesicles 
from KB-Vi cells, The plasma membrane v sicles were SUSl~nd~l in
TS buffer at room temperature. Creatine kinase and creatine phos- 
phate (final concentrations 3 ,ug/100 pl, and 3 raM. reslre.etivaly) were 
added together with ATP (0.33 mM final concentration), and after a 
1 rain equilibration ['~Hlvinblastine (5.3 nM final concentration) was 
added, The final concentration f MgCI2 was 3.3 raM. Plasma mem- 
brane protein content was 50-100pg in the assay (o). Drug uptake 
without he ATP-regenerative system was tested either in the presen~ 
of 0,33 mM ATP (A) or of 3.3 mM ATP (e), Each value is the mean 
of quadruplicates and is corrected by the respective uptake at 0 rain. 
The overshoot in vinblastine uptake at 5 rain was not observed in all 
batches of plasma membrane v sicles, nor was it ~'en with the other 
nueleotides tested. 
3. RESULTS AND DISCUSSION 
3.1. Opthnization of the [~H]vh~blastine uptake condi- 
tions in KB-VI vesicles in the presence of A TP to 
allow screenhzg of other potential energy sources 
..Previous tudies have demonstrated that the plasma 
membrane vesicle population isolated from the mui- 
tidrug-resistant cell line, KB-VI, was able to accumu- 
late vinblastine in a saturable manner, whereas vesicles 
from the drug-sensitive parent cell line (KB-3-1) showed 
very low drug uptake [9]. In agreement with Horio et al. 
[7] we have shown that 0.33 mM ATP, supplemented 
with the ereatine phosphate/creatine phosphokinase 
system, achieves a steady-state level of vinblastine up- 
take which reaches a plateau at 20 rain (Fig. 1). To be 
able to screen for other potential energy sources, the 
regenerative system for ATP has been omitted to avoid 
interference with the tested nucleotide or with nucleo- 
tide combinations. Results shown in Fig. 1 show that 
omitting the ATP regenerating system in the presence 
of the low concentration f ATP (0.33 mM) resulted in 
a substantial decrease indrug uptake compared to levels 
obtained when the regenerating system was present. 
This very same level of  uptake was restored when a 
10-fold higher concentration of  ATP (3.3 raM) was sup- 
plied to the vesicle system. Furthermore the vinblastine 
accumulation profile seen with the ATP regenerating 
system is conserved with this high con~ntration of 
ATP. 
3.2. Characteri-ation of [~H]vinblastine uptake in the 
presence of different nucleotides Or KB- VI vesicles 
3.2.1. Effect of GTP on vinblastine uptake 
Because GTP has been shown to bind to P-glycopro- 
tein [15] and because it is known to substitute for ATP 
in other transport processes [16], GTP was tested for its 
capacity to support vinblastine uptake in KB-VI vesi- 
cles. Fig. 2 shows that drug uptake in the presence of 
3.3 mM GTP also reached a plateau after 20 rain, with 
an average for different membrane preparations of 70- 
80% of the level obtained with the same concentration 
of ATP. 
Osmotic sensitivity studies are a classical approach 
used to demonstrate the presence of 'true' transport. 
The increase in the extravesicular osmotic pressure pro- 
vokes not only a decrease of  the intravesicular space 
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Fig, 2. Time.course ofvinblastine uptake in KB-VI vesicles tested for 
GTP as energy source. Membrane vesicles were suspended in TS 
buffer without he ATP regenerating system and assayed for uptake 
in the presence of 3.3 mM of purine nucleotide as described in Fig, I. 
Uptake with ATP (o). OTP (e), and in the absence of nucleotide 
(control, (A) was measured. The reported values are the mean of 
quadruplicates and were corrected by subtracting their corresponding 
vinblastine uptake values at 0 min, but the uptake value of tile control 
vesicles (without nucleotide) was not subtracted. 
resulting in lower uptake capacity, but may also induce 
a collapse of steric interactions in the architecture ofthe 
transporter, which in turn alters its function. Under the 
same conditions the non-specific binding of the lipo- 
philic drugs to the hydrophobic omponents of the 
membrane is barely affected. Therefore, the osmotic 
sensitivity of the [3H]vinblastine accumulation i KB- 
V1 vesicles was examined to determine whether drug 
accumulation was due to binding or to transport. This 
experiment requires preincubation f the vesicles at dif- 
ferent sucrose concentrations and the demonstration 
that the vesicles do not show leakage at room tempera- 
ture durig this preincubation. The [~H]vinblastine accu- 
mulation curves in the presence of ATP (Figs. 1,2) 
showed no loss of radioactivity associated with the ves- 
icles up to 90 rain after addition of the drug. Therefore 
a ore-incubation f 1 h at different sucrose concentra- 
tions in tide absence of drug and energy source has been 
chosen, followed by 10 min in the presence of the drug 
and of the nucleotide tested• Results obtained under 
these conditions showed different levels of total 
vinblastine accumulation compared to our usual uptake 
conditions, since _. :_ ..L...~ :_ .~. a v e-.,c.,~,,m,~n .. , e absence of any 
nucleotide will deplete the vesicle system of endogenous 
energy. Fig. 2 shows that GTP increased the amount of 
radioactivity associated with vesicles incubated with 
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Fig. 3, Osmotic sensitivity of vinblastine uptake in the presence of 
purine nuclcotides. Vesicles from KB-VI ~lls were ore-incubated in 
TS buffer containing different concentrations of ucrose for 60 rain at 
25~C, The sucrose concentration f the uptake reagents was adjusted 
to be the same as mat of the vesicle suspension, Vinblastine uptake 
was started after this pre-incubation time by the addition of 5,3 nM 
{'~H]vinblastinc with the nucleotide being tested (3,3 raM) and MgCh 
(3.3 mM final concentration). Uptake was measured 10 rain thereafter, 
Uptake was performed either in the presence of ATP (o) or GTP (e) 
or AMP-PNP (A) or in the absence of nucleotide (n). Experimental 
data were corrected by subtracting their corresponding vinblastine 
uptake values at 0 rain. but the uptake value of the control vesicles 
(without nucleofide) was not subtracted. 
[-aH]vinblastine when compared to the control, e.g. in 
the absence of nucleotide. With increasing osmotic pres- 
sure, from 0.25-0.50 M sucrose, both ATP- and GTP- 
mediated transport showed adramatic decrease (Fig. 3): 
from 4.16 + 0.41 to 1.40 + 0.17 and fi'om 3.12 + 0.17 to 
0.98 __. 0.27 pmol vinblastine/mg protein, respectively. 
Under the same conditions no change in the uptake of 
vinblastine by control vesicles or by vesicles incubated 
in the presence of AMP-PNP, a non-hydrolyzable ana- 
log of ATP, was seen. The strong inhibition obtained by 
increasing the osmotic pressure, and the absence of up- 
take in the presence of AMP-PNP, demonstrates that 
this vinblastine association is related to an energy-de- 
pendent transport process. 
Among other compounds tested (U'I'P, CTP, ITP, 
AMP, ADP, NAD ÷, NADP ÷, NADH and NADPH) 
only ITP and ADP showed slightly more uptake of 
[3H]vinblastine into vesicles when compared to the con- 
trol without any nucleotides at 0.25 M sucrose (Fig. 4). 
ITP-supported uptake went from 1.22 to 0.40 pmol 
vinblastine/mg protein in 0.5 M sucrose, and ADP.sup- 
ported uptake went from 1.24 to 0.05 pmol/mg protein. 
These results may reflect he activity of ITP to support 
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Fig. 4, Uptake of vinblastine in the presence of other nucleotides, 
Results are given in % of uptake measured in 0.25 M sucrose in the 
absence of any nueleotide, The uptake of  control vesicles (in the 
absence of nucleotide) was taken as 1 to enable comparison of  non- 
specific vinblastine uptake for different nucleotides in different 
batches of vesicles. The KB-VI plasma membrane vesicles were inca. 
bated in TS buffer containing either 0.25 or 0.50 M sucrose, and 
experimental conditions were the same as in ~ig. 3. Experimental data 
were also corrected by subtracting their corresponding vinblastine 
uptake values at 0 rain, but the uptake value of the control vesicles 
(without nucleotide) was not subtracted. 
transport, and ADP may be able to regenerate ATP via 
endogenous phosphotransferases. Alternatively it is 
also possible that ADP and/or ITP have a direct stimu- 
latory effect in this system, perhaps by occupying an 
allosteric nucleotide-binding site on P-glycoprotein, 
which also may stimulate a single round of transport. 
As noted these osmotic sensitivity experiments gave 
somewhat different uptake values than the kinetic ex- 
periments shown in Figs. i and 2. Although the experi- 
mental conditions do not allow direct comparison of 
kinetic data with data obtained in osmosensitivity ex- 
periments, results how that the effect of ATP or GTP 
was quantitatively similar and that in vitro, GTP can 
substitute for ATP to support vinblastine transport in 
vitro. In Fig. 4, the level of uptake in the absence of any 
nucleotide at 0.25 M sucrose was taken as a reference 
to follow the osmosensitivity of vinblastine uptake with 
other nucleotides/nucleosides and to be able to compare 
several batches of membrane v sicles, indeed, there was 
some variation in levels of transport activity among the 
different vesicle preparations, but transport kinetics are 
consistent within each individual batch of membrane 
vesicles derived from a single cell population. This kind 
of variation has been previously reported when cultured 
cells were used. For instance, variations in purine nucle- 
oside transport from different BHK membrane vesicles 
may range from 40 to 190 pmol/20min/mg membrane 
Time (rnln.) 
Fig. 5. [3Fl]vinblastine uptake in KB.VI vesicles in the presmce of 
different purine nucleotides. Membrane vesicles were a.,,sayed Ibr up- 
take in the presence of 5,3 nM [~Hlvinblastine and in the presence of 
MgCI: in a molar ratio of 2:l to the naeleotide(s). Uptake was meas. 
ured after l0 and 20 rain incubations. The control was vinblastine 
uptake in the absence of any nu¢leotide. Uptake values are the mean 
of triplicates and were corrected for their values at 0 rain. Accumula- 
tion values obtained in the absence of any nucleotide were not sub- 
iracted from the plotvzd values. 
[14]. The relative low yield of purified plasma mem- 
brane vesicles (-10 mg total protein deriving from 60 
plates of 150 mm diameter) and the amount of protein 
required for one set (--400-800/~g protein/data point) 
of experiments limits the number of samples which can 
be run with a particular batch of vesicles. 
3.2.2. [aH]Vinblastine uptake with ATP-GTP 
Our results in Figs. 3 and 4 show an energy require- 
ment for a purine nucleotide triphosphate. Further up- 
take experiments were performed with equimolar con- 
centrations of the combined purine nucleotides. Fig. 5 
shows that an increase in the concentration of ATP 
from 3.3 to 6.6 mM slightly stimulated transport further 
at 10 rain but showed no differences at20 rain, whereas 
a similar increase in the concentration f G'I'P resulted 
in no increase in vinblastine-associated transport at 10 
rain but showed the same increase at 20 min. This obser- 
vation is consistent with the slower GTP-associated ac- 
cumulation also shown in Fig. 2. Several ¢quimolar 
combinations ofboth nucleotides have b~n tested (data 
not shown), and, as for the 3.3 mM combination de- 
picted in Fig. 5, neither an additive ffect nor a synergis- 
tic effect was observed. 
3,2,3, Substitution of GTP for ATP: general considera- 
tions 
In all of these experiments (Figs. 2-5) the somewhat 
lower ability of GTP compared to ATP to support 
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transport could be related to the fact that for GTP the 
transport conditions are not optimal for this nucleotide- 
driven process. This may not be related to the concen- 
tration of the nucleotide chosen but rather may reflect 
either another ion or co-factor requirement for the 
transport process. Alternatively the lower ability of 
GTP alone to sustain vinblastine transport could also 
be related to its intrinsic lower efficiency as an energy 
source for P-glycoprotein. It is also not excluded that, 
in vitro, this GTP for ATP substitution acts as a rescue 
system to prevent ATP depletion, As noted, using sev- 
eral equimolar combinations of both purine nucleotide 
triphosphates there was neither a synergistic nor an 
additive effect on uptake. 
Based on sequence analysis of P-glycoprotein there 
are two nucleotide binding sites, both of" which are es- 
sential for function [17]. One of them could be directly 
related to drug transport, the second site having a regu- 
latory role. Alternatively, each of them might also sup- 
port part of the transport system. The inability of GTP  
to fully replace ATP  might therefore be related to the 
fact that GTP  binds either only to one of the nucleotide 
binding sites or with different affinities to both sites. 
In this study we have emphasized the requirement for 
a purin¢ nucleotide triphosphate in the multidrug trans- 
port process. P- Glycoprotein behaves, therefore, like 
other transporter/permease systems where GTP  can 
substitute for ATP  [I 6]. Our observations are also con- 
sistent with the inhibitory effect of  ATP or GTP on 
photoaffinity labelling with 8-azido-ATP of P-glyeopro- 
tein performed on KB-V1 vesicles [15]. The use of 
plasma membrane vesicles is a first step in studying the 
function of the multidrug transporter. This model ena- 
bled the screening of molecules capable of providing 
energy for drug accumulation, and will serve, as well, 
for the screening of molecules capable of altering trans- 
porter function. Furthermore, this vesicle system consti- 
tutes the reference tbr a more defined model, consisting 
of purified P-glycoprotein insert=d in a known lipid 
environment. Further studies with such a 'reconstituted 
system' derived from the in vitro transport system will 
be needed to determine not ony the stoichiometries of
the molecules involved in the transport process, but also 
the precise mechanism of action of ATP and GTP in 
providing energy and regulating the transport process. 
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